
==== Front
Adv Ther
Adv Ther
Advances in Therapy
0741-238X 1865-8652 Springer Healthcare Communications Heidelberg 

72
10.1007/s12325-011-0072-7
Review
Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
Smith James R. james.smith.js1@roche.com 1 Rayner Craig R. 23 Donner Barbara 1 Wollenhaupt Martina 1 Klumpp Klaus 4 Dutkowski Regina 4 1 grid.417570.00000000403741269Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, PBMT Bldg 74/3O Z1.06, CH-4070 Basel, Switzerland 
2 Roche Products Pty Ltd, Melbourne, Australia 
3 grid.1002.30000000419367857Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia 
4 grid.418158.10000000405344718Hoffmann-La Roche, Inc., Nutley, NJ USA 
1 11 2011 
1 11 2011 
2011 
28 11 927 959
8 8 2011 © Springer Healthcare 2011This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Oseltamivir (Tamiflu®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) is an orally administered antiviral for the treatment and prevention of influenza A and B infections that is registered in more than 100 countries worldwide. More than 83 million patients have been exposed to the product since its introduction. Oseltamivir is recommended by the World Health Organization (WHO) for use in the clinical management of pandemic and seasonal influenza of varying severity, and as the primary antiviral agent for treatment of avian H5N1 influenza infection in humans. This article is a nonsystematic review of the experience gained from the first 10 years of using oseltamivir for influenza infections since its launch in early 2000, emphasizing recent advances in our understanding of the product and its clinical utility in five main areas. The article reviews the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate, including information on special populations such as children and elderly adults, and the co-administration of oseltamivir with other agents. This is followed by a summary of data on the effectiveness of oseltamivir treatment and prophylaxis in patients with all types of influenza, including pandemic (H1N1) 2009 and avian H5N1 influenza. The implications of changes in susceptibility of circulating influenza viruses to oseltamivir and other antiviral agents are also described, as is the emergence of antiviral resistance during and after the 2009 pandemic. The fourth main section deals with the safety profile of oseltamivir in standard and special patient populations, and reviews spontaneously reported adverse event data from the pandemic and pre-pandemic periods and the topical issue of neuropsychiatric adverse events. Finally, the article considers the pharmacoeconomics of oseltamivir in comparison with vaccination and usual care regimens, and as a component of pandemic influenza mitigation strategies.

Keywords
avianefficacyinfluenzaoseltamivirpandemicpharmacoeconomicspharmacokineticsresistancesafetyseasonalissue-copyright-statement© Springer Healthcare 2011
==== Body
This article is published with open access at Springerlink.com
==== Refs
References
1. Centers for Disease Control and Prevention (CDC). Key facts about influenza (flu) and flu vaccine. Revised 3 June 2010. Available at: http://www.cdc.gov/flu/keyfacts.htm. Last accessed September 2, 2010.
2. Thompson W.W.  Shay D.K.  Weintraub E.    Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 2003 289 179 186 10.1001/jama.289.2.179 12517228 
3. Thompson W.W.  Shay D.K.  Weintraub E.    Influenza-associated hospitalizations in the United States JAMA 2004 292 1333 1340 10.1001/jama.292.11.1333 15367555 
4. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic Bautista E.  Chotpitayasunondh T.    Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection N Engl J Med 2010 362 1708 1719 10.1056/NEJMra1000449 20445182 
5. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO: 19 November 2010. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_11_19/en/index.html. Last accessed September 1, 2010.
6. Tamiflu SmPC. Tamiflu Summary of Product Characteristics. 2011. Available at: http://www.medicines.org.uk/emc/. Last accessed September 2, 2010.
7. Tamiflu PI. Tamiflu Prescribing Information. 2011. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Search_Drug_Name. Last accessed September 2, 2010.
8. Moscona A.   Neuraminidase inhibitors for influenza N Engl J Med 2005 353 1363 1373 10.1056/NEJMra050740 16192481 
9. World Health Organization (WHO). WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised February 2010. Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/index. html. Last accessed September 1, 2010.
10. Health Protection Agency. Pharmacologicial treatment and prophylaxis of influenza. Version 1.7. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287147812045. Last accessed January 12, 2011.
11. World Health Organization (WHO). Clinical management of human infection with avian influenza A (H5N1) virus. 15 August 2007. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf. Last accessed September 1, 2010.
12. Adisasmito W.  Chan P.K.  Lee N.    Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry J Infect Dis 2010 202 1154 1160 10.1086/656316 20831384 
13. He G.  Massarella J.  Ward P.   Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 Clin Pharmacokinet 1999 37 471 484 10.2165/00003088-199937060-00003 10628898 
14. Roberts NA, Wiltshire HR, Mendel DB, Webster RG. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. ASM Biodefense Research Meeting. Baltimore, Maryland, USA. March 9–12, 2003. Abstract.
15. World Health Organization  Update on oseltamivir-resistant pandemic (H1N1) 2009 influenza virus: January 2010 Wkly Epidemiol Rec 2010 85 37 48 
16. Stoner T.D.  Krauss S.  DuBois R.M.    Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype J Virol 2010 84 9800 9809 10.1128/JVI.00296-10 20660186 
17. Kurowski M.  Oo C.  Wiltshire H.  Barrett J.   Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses Clin Drug Invest 2004 24 49 53 10.2165/00044011-200424010-00006 
18. Jhee S.S.  Yen M.  Ereshefsky L.    Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers Antimicrob Agents Chemother 2008 52 3687 3693 10.1128/AAC.00327-08 18676886 
19. Abe M.  Smith J.  Urae A.    Pharmacokinetics of oseltamivir in young and very elderly subjects Ann Pharmacother 2006 40 1724 1730 10.1345/aph.1H174 16940405 
20. Schentag J.J.  Hill G.  Chu T.  Rayner C.R.   Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects J Clin Pharmacol 2007 47 689 696 10.1177/0091270007299761 17456583 
21. Oo C.  Barrett J.  Hill G.    Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children Paediatr Drugs 2001 3 229 236 10.2165/00128072-200103030-00005 11310719 
22. Strolin Benedetti M.  Whomsley R.  Baltes E.L.   Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations Expert Opin Drug Metab Toxicol 2005 1 447 471 10.1517/17425255.1.3.447 16863455 
23. Vogt B.A.  Davis I.D.  Avner E.D.   Klaus M.H.  Fanaroff A.A.   The kidney Care of the highrisk neonate 2001 5th Edition Pennsylvania Saunders 426 427 
24. Acosta E.P.  Kimberlin D.W.   Determination of appropriate dosing of influenza drugs in pediatric patients Clin Pharmacol Ther 2010 88 704 707 10.1038/clpt.2010.173 20881956 
25. Acosta E.P.  Jester P.  Gal P.    Oseltamivir dosing for influenza infection in premature neonates J Infect Dis 2010 202 563 566 10.1086/654930 20594104 
26. Worley K.C.  Roberts S.W.  Bawdon R.E.   The metabolism and transplacental transfer of oseltamivir in the ex vivo human model Infect Dis Obstet Gynecol 2008 2008 927574 18551180 
27. Wentges-van H.N.  van Eijkeren M.  van der Laan J.W.   Oseltamivir and breastfeeding Int J Infect Dis 2008 12 451 10.1016/j.ijid.2007.11.009 18243025 
28. Robson R.  Buttimore A.  Lynn K.  Brewster M.  Ward P.   The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis Nephrol Dial Transplant 2006 21 2556 2562 10.1093/ndt/gfl267 16799169 
29. Snell P.  Dave N.  Wilson K.    Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate Br J Clin Pharmacol 2005 59 598 601 10.1111/j.1365-2125.2005.02340.x 15842560 
30. Morrison D.  Roy S.  Rayner C.    A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination PLoS ONE 2007 2 e1305 10.1371/journal.pone.0001305 18074029 
31. Davies BE, Cirrincione-Dall G, Ballester-Sanchis RM, Navarro MT, Brennen B. Pharmacokinetics and safety of co-administered oseltamivir and rimantadine in healthy subjects: an open-label, multiple-dose, randomised, crossover study. XII International Symposium on Respiratory Viral Infections. Taipei, Taiwan. March 11–14, 2010. Abstract.
32. Oo C.  Barrett J.  Dorr A.  Liu B.  Ward P.   Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin Antimicrob Agents Chemother 2002 46 1993 1995 10.1128/AAC.46.6.1993-1995.2002 12019123 
33. Snell P.  Oo C.  Dorr A.  Barrett J.   Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids Br J Clin Pharmacol 2002 54 372 377 10.1046/j.1365-2125.2002.01678.x 12392584 
34. Hill G.  Cihlar T.  Oo C.    The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies Drug Metab Dispos 2002 30 13 19 10.1124/dmd.30.1.13 11744606 
35. Davies BE, Aceves Baldo P, Brewster M. Effect of oseltamivir on anticoagulation: a crossover study in patients stabilized on warfarin. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 12–15, 2009. Abstract.
36. Aoki F, Lam H, Jeffrey JR, Sitar DS. Oseltamivir does not interact pharmacokinetically with cyclosporine, mycophenolate or tacrolimus in renal transplant patients. Annual Meeting of the Infectious Disease Society of America. San Francisco, CA, USA. October 6–9, 2005. Abstract.
37. Holodniy M.  Penzak S.R.  Straight T.M.    Pharmacokinetics and tolerability of oseltamivir combined with probenecid Antimicrob Agents Chemother 2008 52 3013 3021 10.1128/AAC.00047-08 18559644 
38. Rayner C.R.  Chanu P.  Gieschke R.  Boak L.M.  Jonsson E.N.   Population pharmacokinetics of oseltamivir when coadministered with probenecid J Clin Pharmacol 2008 48 935 947 10.1177/0091270008320317 18524996 
39. Treanor J.J.  Hayden F.G.  Vrooman P.S.    Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group JAMA 2000 283 1016 1024 10.1001/jama.283.8.1016 10697061 
40. Nicholson K.G.  Aoki F.Y.  Osterhaus A.D.    Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group Lancet 2000 355 1845 1850 10.1016/S0140-6736(00)02288-1 10866439 
41. Kaiser L.  Wat C.  Mills T.    Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations Arch Intern Med 2003 163 1667 1672 10.1001/archinte.163.14.1667 12885681 
42. Welliver R.  Monto A.S.  Carewicz O.    Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial JAMA 2001 285 748 754 10.1001/jama.285.6.748 11176912 
43. Hayden F.G.  Belshe R.  Villanueva C.    Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis J Infect Dis 2004 189 440 449 10.1086/381128 14745701 
44. Hayden F.G.  Atmar R.L.  Schilling M.    Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza N Engl J Med 1999 341 1336 1343 10.1056/NEJM199910283411802 10536125 
45. Peters P.H. Jr.  Gravenstein S.  Norwood P.    Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population J Am Geriatr Soc 2001 49 1025 1031 10.1046/j.1532-5415.2001.49204.x 11555062 
46. Whitley R.J.  Hayden F.G.  Reisinger K.S.    Oral oseltamivir treatment of influenza in children Pediatr Infect Dis J 2001 20 127 133 10.1097/00006454-200102000-00002 11224828 
47. Winther B.  Block S.L.  Reisinger K.  Dutkowski R.   Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza Int J Pediatr Otorhinolaryngol 2010 74 684 688 10.1016/j.ijporl.2010.03.024 20363510 
48. Reisinger K, Marcadis I, Cupelli LA, Shu D. Oseltamivir for prevention of seasonal influenza in children. Options for the Control of Influenza VI. Toronto, Canada. June 17–23, 2007. Abstract.
49. Sugaya N.  Mitamura K.  Yamazaki M.    Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children Clin Infect Dis 2007 44 197 202 10.1086/509925 17173216 
50. Sugaya N.  Tamura D.  Yamazaki M.    Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children Clin Infect Dis 2008 47 339 345 10.1086/589748 18582202 
51. Barr C.E.  Schulman K.  Iacuzio D.  Bradley J.S.   Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza Curr Med Res Opin 2007 23 523 531 10.1185/030079906X167499 17355734 
52. Piedra P.A.  Schulman K.L.  Blumentals W.A.   Effects of oseltamivir on influenza-related complications in children with chronic medical conditions Pediatrics 2009 124 170 178 10.1542/peds.2008-0977 19564297 
53. Johnston S.L.  Ferrero F.  Garcia M.L.  Dutkowski R.   Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenzainfected children with asthma Pediatr Infect Dis J 2005 24 225 232 10.1097/01.inf.0000154322.38267.ce 15750458 
54. Lin J.T.  Yu X.Z.  Cui D.J.    A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population Curr Med Res Opin 2006 22 75 82 10.1185/030079906X80297 16393433 
55. Chemaly R.F.  Ghosh S.  Bodey G.P.    Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center Medicine (Baltimore) 2006 85 278 287 10.1097/01.md.0000232560.22098.4e 16974212 
56. Peters P.H.  Moscona A.  Schulman K.L.  Barr C.E.   Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000–2005 Medscape J Med 2008 10 131 18679536 
57. McGeer A.  Green K.A.  Plevneshi A.    Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada Clin Infect Dis 2007 45 1568 1575 10.1086/523584 18190317 
58. Lee N.  Choi K.W.  Chan P.K.    Outcomes of adults hospitalised with severe influenza Thorax 2010 65 510 515 10.1136/thx.2009.130799 20522848 
59. Dutkowski R.   Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients J Antimicrob Chemother 2010 65 Suppl.2 ii11 ii24 10.1093/jac/dkq012 20215131 
60. Ward P.  Small I.  Smith J.  Suter P.  Dutkowski R.   Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic J Antimicrob Chemother 2005 55 Suppl.1 i5 i21 10.1093/jac/dki018 15709056 
61. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev. 2007;CD002744.
62. Jefferson T.  Jones M.  Doshi P.  Del Mar C.   Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis BMJ 2009 339 b5106 10.1136/bmj.b5106 19995812 
63. Ruf B.R.  Szucs T.   Reducing the burden of influenzaassociated complications with antiviral therapy Infection 2009 37 186 196 19471854 
64. Hernan M.A.  Lipsitch M.   Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials Clin Infect Dis 2011 53 277 279 10.1093/cid/cir400 21677258 
65. Aoki F.Y.  Macleod M.D.  Paggiaro P.    Early administration of oral oseltamivir increases the benefits of influenza treatment J Antimicrob Chemother 2003 51 123 129 10.1093/jac/dkg007 12493796 
66. Kawai N.  Ikematsu H.  Iwaki N.    A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons Clin Infect Dis 2006 43 439 444 10.1086/505868 16838232 
67. Heinonen S.  Silvennoinen H.  Lehtinen P.    Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial Clin Infect Dis 2010 51 887 894 10.1086/656408 20815736 
68. Writing Committee of the Second World Health Organization Consultationon Clinical Aspects of Human Infection with Avian Influenza A  Update on avian influenza A (H5N1) virus infection in humans N Engl J Med 2008 358 261 273 10.1056/NEJMra0707279 18199865 
69. Gambotto A.  Barratt-Boyes S.M.  de Jong M.D.  Neumann G.  Kawaoka Y.   Human infection with highly pathogenic H5N1 influenza virus Lancet 2008 371 1464 1475 10.1016/S0140-6736(08)60627-3 18440429 
70. Kandun I.N.  Tresnaningsih E.  Purba W.H.    Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series Lancet 2008 372 744 749 10.1016/S0140-6736(08)61125-3 18706688 
71. Liem N.T.  Tung C.V.  Hien N.D.    Clinical features of human influenza A (H5N1) infection in Vietnam: 2004–2006 Clin Infect Dis 2009 48 1639 1646 10.1086/599031 19435433 
72. Hien N.D.  Ha N.H.  Van N.T.    Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004–2005 Emerg Infect Dis 2009 15 19 23 10.3201/eid1501.080073 19116044 
73. Smith J.R.   Oseltamivir in human avian influenza infection J Antimicrob Chemother 2010 65 Suppl.2 ii25 ii33 10.1093/jac/dkq013 20215132 
74. World Health Organization (WHO). Pandemic (H1N1) 2009 — update 112. 6 August 2010. Available at: http://www.who.int/csr/don/2010_08_06/en/index.html. Last accessed September 1, 2010.
75. Li I.W.  Hung I.F.  To K.K.    The natural viral load profile of patients with pandemic swine-origin influenza A H1N1 2009 (pH1N1) and the effect of oseltamivir treatment Chest 2010 137 759 768 10.1378/chest.09-3072 20061398 
76. Cao B.  Li X.W.  Mao Y.    Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China N Engl J Med 2009 361 2507 2517 10.1056/NEJMoa0906612 20007555 
77. Ling L.M.  Chow A.L.  Lye D.C.    Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection Clin Infect Dis 2010 50 963 969 10.1086/651083 20180701 
78. Hien T.T.  Boni M.F.  Bryant J.E.    Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis PLoS Med 2010 7 e1000277 10.1371/journal.pmed.1000277 20502525 
79. Lee N.  Chan P.K.  Hui D.S.    Viral loads and duration of viral shedding in adult patients hospitalized with influenza J Infect Dis 2009 200 492 500 10.1086/600383 19591575 
80. Jain S.  Kamimoto L.  Bramley A.M.    Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009 N Engl J Med 2009 361 1935 1944 10.1056/NEJMoa0906695 19815859 
81. Farias J.A.  Fernandez A.  Monteverde E.    Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina Intensive Care Med 2010 36 1015 1022 10.1007/s00134-010-1853-1 20237757 
82. Dominguez-Cherit G.  Lapinsky S.E.  Macias A.E.    Critically ill patients with 2009 influenza A(H1N1) in Mexico JAMA 2009 302 1880 1887 10.1001/jama.2009.1536 19822626 
83. Chien Y.S.  Su C.P.  Tsai H.T.    Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan J Infect 2010 60 168 174 10.1016/j.jinf.2009.12.012 20036689 
84. Centers for Disease ControlPrevention.  Patients hospitalized with 2009 pandemic influenza A (H1N1) — New York City, May 2009 MMWR Morb Mortal Wkly Rep 2010 58 1436 1440 20057350 
85. Campbell C.N.  Mytton O.T.  McLean E.M.    Hospitalization in two waves of pandemic influenza A(H1N1) in England Epidemiol Infect 2011 139 1560 1569 10.1017/S0950268810002657 21108872 
86. Lee E.H.  Wu C.  Lee E.U.    Fatalities associated with the 2009 H1N1 influenza A virus in New York city Clin Infect Dis 2010 50 1498 1504 10.1086/652446 20420514 
87. Louie J.K.  Acosta M.  Jamieson D.J.  Honein M.A.   Severe 2009 H1N1 influenza in pregnant and postpartum women in California N Engl J Med 2010 362 27 35 10.1056/NEJMoa0910444 20032319 
88. Siston A.M.  Rasmussen S.A.  Honein M.A.    Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States JAMA 2010 303 1517 1525 10.1001/jama.2010.479 20407061 
89. Creanga A.A.  Johnson T.F.  Graitcer S.B.    Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women Obstet Gynecol 2010 115 717 726 10.1097/AOG.0b013e3181d57947 20308830 
90. Kumar D.  Michaels M.G.  Morris M.I.    Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study Lancet Infect Dis 2010 10 521 526 10.1016/S1473-3099(10)70133-X 20620116 
91. Louie J.K.  Acosta M.  Winter K.    Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California JAMA 2009 302 1896 1902 10.1001/jama.2009.1583 19887665 
92. Torres J.P.  O’Ryan M.  Herve B.    Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile Clin Infect Dis 2010 50 860 868 10.1086/650750 20166819 
93. Institut de Veille Sanitaire (InVS). Benefit of early antiviral therapy in reducing the severity and mortality of influenza A (H1N1) 2009: data obtained from serious infection monitoring [French]. Available at: http://www.invs.sante.fr/surveillance/grippe_dossier/docs_professionnels/antiviraux_grippe_a_h1n1_211209.pdf. Last accessed February 19, 2010.
94. Zarychanski R.  Stuart T.L.  Kumar A.    Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection CMAJ 2010 182 257 264 10.1503/cmaj.091884 20093297 
95. Lee V.J.  Yap J.  Cook A.R.    Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks N Engl J Med 2010 362 2166 2174 10.1056/NEJMoa0908482 20558367 
96. Komiya N.  Gu Y.  Kamiya H.    Household transmission of pandemic 2009 influenza a (H1N1) virus in Osaka, Japan in May 2009 J Infect 2010 61 284 288 10.1016/j.jinf.2010.06.019 20670650 
97. Leung Y.H.  Li M.P.  Chuang S.K.   A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir Epidemiol Infect 2011 139 41 44 10.1017/S0950268810001445 20561390 
98. Aoki F.Y.  Boivin G.  Roberts N.   Influenza virus susceptibility and resistance to oseltamivir Antivir Ther 2007 12 603 616 17944268 
99. Dharan N.J.  Gubareva L.V.  Meyer J.J.    Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States JAMA 2009 301 1034 1041 10.1001/jama.2009.294 19255110 
100. Hauge S.H.  Dudman S.  Borgen K.  Lackenby A.  Hungnes O.   Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08 Emerg Infect Dis 2009 15 155 162 10.3201/eid1502.081031 19193257 
101. Kiso M.  Mitamura K.  Sakai-Tagawa Y.    Resistant influenza A viruses in children treated with oseltamivir: descriptive study Lancet 2004 364 759 765 10.1016/S0140-6736(04)16934-1 15337401 
102. Stephenson I.  Democratis J.  Lackenby A.    Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children Clin Infect Dis 2009 48 389 396 10.1086/596311 19133796 
103. Toovey S.  Rayner C.  Prinssen E.    Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review Drug Saf 2008 31 1097 1114 19026027 
104. NISN.  Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons Wkly Epidemiol Rec 2007 82 149 150 17465078 
105. Monto A.S.  McKimm-Breschkin J.L.  Macken C.    Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use Antimicrob Agents Chemother 2006 50 2395 2402 10.1128/AAC.01339-05 16801417 
106. Sheu T.G.  Deyde V.M.  Okomo-Adhiambo M.    Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008 Antimicrob Agents Chemother 2008 52 3284 3292 10.1128/AAC.00555-08 18625765 
107. Meijer A.  Lackenby A.  Hungnes O.    Oseltamivirresistant influenza virus A (H1N1), Europe, 2007–08 Season Emerg Infect Dis 2009 15 552 560 10.3201/eid1504.081280 19331731 
108. Kramarz P.  Monnet D.  Nicoll A.  Yilmaz C.  Ciancio B.   Use of oseltamivir in 12 European countries between 2002 and 2007 — lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses Euro Surveill 2009 14 pii19112 
109. Goddard N.  Zucs P.  Ciancio B.    Start of the influenza season 2008–9 in Europe — increasing influenza activity moving from West to East dominated by A(H3N2) Euro Surveill 2009 14 ii 19097 19161722 
110. Centers for Disease ControlPrevention  Update: influenza activity — United States, September 28, 2008–April 4, 2009, and composition of the 2009/10 influenza vaccine MMWR Morb Mortal Wkly Rep 2009 58 369 374 19373198 
111. Rameix-Welti M.A.  Enouf V.  Cuvelier F.  Jeannin P.  van der Werf S.   Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir PLoS Pathog 2008 4 e1000103 10.1371/journal.ppat.1000103 18654625 
112. Bloom J.D.  Gong L.I.  Baltimore D.   Permissive secondary mutations enable the evolution of influenza oseltamivir resistance Science 2010 328 1272 1275 10.1126/science.1187816 20522774 
113. Hurt A.C.  Selleck P.  Komadina N.    Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes Antiviral Res 2007 73 228 231 10.1016/j.antiviral.2006.10.004 17112602 
114. Hill A.W.  Guralnick R.P.  Wilson M.J.  Habib F.  Janies D.   Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza Infect Genet Evol 2009 9 169 178 10.1016/j.meegid.2008.10.006 19022400 
115. de Jong M.D.  Tran T.T.  Truong H.K.    Oseltamivir resistance during treatment of influenza A (H5N1) infection N Engl J Med 2005 353 2667 2672 10.1056/NEJMoa054512 16371632 
116. Le Q.M.  Kiso M.  Someya K.    Avian flu: isolation of drug-resistant H5N1 virus Nature 2005 437 1108 10.1038/4371108a 16228009 
117. Earhart K.C.  Elsayed N.M.  Saad M.D.    Oseltamivir resistance mutation N294S in human influenza A (H5N1) virus in Egypt J Infect Public Health 2009 2 74 80 10.1016/j.jiph.2009.04.004 20701864 
118. World Health Organization (WHO). Weekly virological update. 26 August 2010. Available at: http://www.who.int/csr/disease/swineflu/notes/briefing_20091202/en/index.html. Last accessed September 2, 2010.
119. Garten R.J.  Davis C.T.  Russell C.A.    Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans Science 2009 325 197 201 10.1126/science.1176225 19465683 
120. World Health Organization (WHO). Update on oseltamivir resistance in influenza A(H1N1)2009 viruses. 10 August 2011. Available at: http://www.who.int/influenza/surveillance_monitoring/updates/2011_08_12_weekly_web_update_oseltamivir_resistance.pdf. Last accessed January 12, 2011.
121. Hayden F.G.   Mayers D.L.   Antiviral resistance in influenza viruses: clinical and epidemiological aspects Antimicrobial Drug Resistance 2009 New York Humana Press 1011 1034 
122. Harvala H.  Gunson R.  Simmonds P.    The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November–December, 2009 Euro Surveill 2010 15 pii19536 
123. Tramontana A.R.  George B.  Hurt A.C.    Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia Emerg Infect Dis 2010 16 1068 1075 10.3201/eid1607.091691 20587176 
124. Rousset D, Le Goff J, Abou-Jaoude G. Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptibility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors. Options for the Control of Influenza. Hong Kong. September 3–7, 2010. Abstract.
125. van der Vries E.  Stelma F.F.  Boucher C.A.   Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus N Engl J Med 2010 363 1381 1382 10.1056/NEJMc1003749 20879894 
126. World Health Organization. Weekly update on oseltamivir resistance to influenza A (H1N1) 2009 viruses. Available at: http://www.who.int/csr/disease/swineflu/oseltamivirresistant20100820.pdf. Last accessed September 1, 2010.
127. Baz M.  Abed Y.  Papenburg J.    Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis N Engl J Med 2009 361 2296 2297 10.1056/NEJMc0910060 19907034 
128. Centers for Disease ControlPrevention.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis — North Carolina, 2009 MMWR Morb Mortal Wkly Rep 2009 58 969 972 19745803 
129. World Health Organization  Oseltamivirresistant pandemic (H1N1) 2009 influenza virus, October 2009 Wkly Epidemiol Rec 2009 84 453 459 19894344 
130. Hamelin M.E.  Baz M.  Abed Y.    Oseltamivirresistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets PLoS Pathog 2010 6 e1001015 10.1371/journal.ppat.1001015 20661429 
131. Duan S.  Boltz D.A.  Seiler P.    Oseltamivirresistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets PLoS Pathog 2010 6 e1001022 10.1371/journal.ppat.1001022 20686654 
132. Kiso M.  Shinya K.  Shimojima M.    Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses PLoS Pathog 2010 6 e1001079 10.1371/journal.ppat.1001079 20865125 
133. Smith E.V.  Pynn M.C.  Blackford S.  Leopold D.J.   Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu) Br J Gen Pract 2010 60 133 134 10.3399/bjgp10X483292 20132714 
134. Wells Q.  Hardin B.  Raj S.R.  Darbar D.   Sotalolinduced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza Heart Rhythm 2010 7 1454 1457 10.1016/j.hrthm.2010.07.025 20656063 
135. Karplus R.  Sanset S.  Zaidenstein R.  Schneider D.  Berkovitch M.   Suspected oseltamivir-induced bradycardia Int J Infect Dis 2010 14 Suppl.3 e374 e375 10.1016/j.ijid.2010.03.009 20615742 
136. Casscells S.W.  Granger E.  Kress A.M.  Linton A.  Madjid M.   Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular disease Circulation 2009 2 108 115 20031822 
137. Madjid M.  Curkendall S.  Blumentals W.A.   The influence of oseltamivir on the risk of stroke after influenza infection Cardiology 2009 113 98 107 10.1159/000172796 19018144 
138. Okabe N.  Yamashita K.  Taniguchi K.  Inouye S.   Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season Pediatr Int 2000 42 187 191 10.1046/j.1442-200x.2000.01206.x 10804740 
139. Kasai T.  Togashi T.  Morishima T.   Encephalopathy associated with influenza epidemics Lancet 2000 355 1558 1559 10.1016/S0140-6736(05)74614-6 10801205 
140. Morishima T.  Togashi T.  Yokota S.    Encephalitis and encephalopathy associated with an influenza epidemic in Japan Clin Infect Dis 2002 35 512 517 10.1086/341407 12173123 
141. United States Food and Drug Administration (FDA). Meeting of the FDA Pediatric Advisory Committee, 16 November 2006. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/oc06.htm. Last accessed July 3, 2008.
142. Casscells S.W.  Granger E.  Kress A.M.  Linton A.   The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza Int J Adolesc Med Health 2009 21 79 89 10.1515/IJAMH.2009.21.1.79 19526698 
143. Donner B, Bader-Weder S, Schwarz R, et al. Safety profile of oseltamivir during the 2009 influenza pandemic. Options for the Control of Influenza, Hong Kong SAR, China. September 3–7, 2010. Abstract.
144. Dutkowski R.  Thakrar B.  Froehlich E.    Safety and pharmacology of oseltamivir in clinical use Drug Saf 2003 26 787 801 10.2165/00002018-200326110-00004 12908848 
145. Reisinger K, Cupelli LA, and Shu D. Seasonal prophylaxis of influenza with oseltamivir in children. 5th Annual Meeting of the World Society for Paediatric Infectious Diseases (WSPID). Bangkok, Thailand. November 15–18, 2007. Abstract.
146. European Medicines Evaluation Agency (EMEA). Assessment report for Tamiflu. London, 24 September 2009. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000402/WC500033109.pdf. Last accessed September 2, 2010.
147. Centers for Disease Control and Prevention (CDC). Interim guidance on antiviral recommendations for patients with novel influenza A (H1N1) virus infection and their close contacts. Updated 7 December 2009. Available at: http://www.cdc.gov/h1n1flu/recommendations.htm. Last accessed September 1, 2010.
148. Siedler K.  Skopnik H.   Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis Pediatr Infect Dis J 2010 29 495 498 20035245 
149. European Medicines Evaluation Agency (EMEA). Opinion of the Committee for Medicinal Products for Human Use pursuant to Article 5(3) of Regulation (EC) No.726/2004, on novel influenza (H1N1) outbreak; Tamiflu (oseltamivir), Relenza (zanamivir). Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500018446.pdf. Last accessed September 1, 2010.
150. Donner B.  Niranhan V.  Hoffmann G.   Safety of oseltamivir in pregnancy: a review of preclinical and clinical data Drug Saf 2010 33 631 642 10.2165/11536370-000000000-00000 20635821 
151. Greer L.G.  Sheffield J.S.  Rogers V.L.    Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications Obstet Gynecol 2010 115 711 716 10.1097/AOG.0b013e3181d44752 20308829 
152. Vu D.  Peck A.J.  Nichols W.G.    Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study Clin Infect Dis 2007 45 187 193 10.1086/518985 17578777 
153. Ison MG, Szakaly P, Shapira MY, et al. Oseltamivir prophylaxis reduces the occurrence of influenza infection in transplant recipients. 14th Annual Congress of the European Society for Organ Transplantation. Paris, France. August 30–September 2, 2009. Abstract.
154. Redelman-Sidi G.   Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure Leuk Lymphoma 2010 51 1954 1956 10.3109/10428194.2010.510226 20858099 
155. Watcharananan S.P.  Suwatanapongched T.  Wacharawanichkul P.    Influenza A/H 1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following highdose oseltamivir exposure Transpl Infect Dis 2010 12 127 131 10.1111/j.1399-3062.2010.00493.x 20102550 
156. Dutkowski R.  Smith J.R.  Davies B.E.   Safety and pharmacokinetics of oseltamivir at standard and high dosages Int J Antimicrob Agents 2010 35 461 467 10.1016/j.ijantimicag.2009.12.023 20189775 
157. Schmidt A.C.   Antiviral therapy for influenza: a clinical and economic comparative review Drugs 2004 64 2031 2046 10.2165/00003495-200464180-00003 15341496 
158. Lynd L.D.  Goeree R.  O’Brien B.J.   Antiviral agents for influenza: a comparison of cost-effectiveness data Pharmacoeconomics 2005 23 1083 1106 10.2165/00019053-200523110-00003 16277546 
159. Postma M.J.  Beardsworth P.  Wilschut J.C.   Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes J Med Econ 2008 11 743 768 10.3111/13696990802505557 19450079 
160. Sander B.  Hayden F.G.  Gyldmark M.  Garrison L.P. Jr.   Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK Pharmacoeconomics 2006 24 373 386 10.2165/00019053-200624040-00007 16605283 
161. Postma M.J.  Novak A.  Scheijbeler H.W.    Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands Pharmacoeconomics 2007 25 497 509 10.2165/00019053-200725060-00005 17523754 
162. Talbird S.E.  Brogan A.J.  Winiarski A.P.  Sander B.   Costeffectiveness of treating influenzalike illness with oseltamivir in the United States Am J Health Syst Pharm 2009 66 469 480 10.2146/ajhp080296 19233995 
163. Nagase H.  Moriwaki K.  Kamae M.  Yanagisawa S.  Kamae I.   Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan Value Health 2009 12 Suppl.3 S62 S65 10.1111/j.1524-4733.2009.00629.x 20586984 
164. Lugner A.K.  Postma M.J.   Mitigation of pandemic influenza: review of cost-effectiveness studies Expert Rev Pharmacoecon Outcomes Res 2009 9 547 558 10.1586/erp.09.56 19941432 
165. Sander B.  Nizam A.  Garrison L.P. Jr    Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model Value Health 2009 12 226 233 10.1111/j.1524-4733.2008.00437.x 18671770

